PSMA-negative Widespread Metastases Identified by 18F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation

A 62-year-old man had prostate cancer treated for 5 years with prostatectomy, radiation, and hormonal therapy. He presented with worsening back pain for 3 months. Serum prostate-specific antigen was very low (<1.0 ng/mL), while neuron-specific enolase was elevated (23.35 ng/mL), raising suspicion of neuroendocrine differentiation. Dual-tracer PET/CT was performed. 68 Ga-PSMA PET/CT showed no recurrence or metastasis, while 18 F-FDG PET/CT revealed widespread hypermetabolic bone lesions and retrocrural nodal disease. Biopsy confirmed treatment-related neuroendocrine prostate cancer with squamous differentiation. This rare phenotype exhibited typical PSMA-negativity and intense FDG uptake. It emphasizes the diagnostic potential of 18 F-FDG PET/CT in dedifferentiated prostate cancers.

Authors

Institutions

Publication Details

Journal
Clinical Nuclear Medicine
Published
2025-08-14
DOI
https://doi.org/10.1097/rlu.0000000000006106
Citations
1
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PSMA-negative Widespread Metastases Identified by 18F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation

Xiaomei Gao, Yongxiang Tang, Shuo Hu, Yujia Li et al.
1 citations
Clinical Nuclear Medicine
Prostate Cancer Treatment and Research
1.52
article

PSMA-negative Widespread Metastases Identified by 18F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation

Xiaomei Gao, Yongxiang Tang, Shuo Hu, Yujia Li, Jinhui Yang
article en
1 citations

Abstract

A 62-year-old man had prostate cancer treated for 5 years with prostatectomy, radiation, and hormonal therapy. He presented with worsening back pain for 3 months. Serum prostate-specific antigen was very low (<1.0 ng/mL), while neuron-specific enolase was elevated (23.35 ng/mL), raising suspicion of neuroendocrine differentiation. Dual-tracer PET/CT was performed. 68 Ga-PSMA PET/CT showed no recurrence or metastasis, while 18 F-FDG PET/CT revealed widespread hypermetabolic bone lesions and retrocrural nodal disease. Biopsy confirmed treatment-related neuroendocrine prostate cancer with squamous differentiation. This rare phenotype exhibited typical PSMA-negativity and intense FDG uptake. It emphasizes the diagnostic potential of 18 F-FDG PET/CT in dedifferentiated prostate cancers.

Clinical Nuclear MedicineVol. 51(1)
Central South University (CN), National Health and Family Planning Commission (CN), Xiangya Hospital Central South University (CN)
Openalex Percentile: Top 15%
Prostate Cancer Treatment and Research
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

PSMA-negative Widespread Metastases Identified by 18F-FDG PET/CT in Treatment-related Neuroendocrine Prostate Cancer With Squamous Differentiation — Xiaomei Gao, Yongxiang Tang, et al. · Clinical Nuclear Medicine (2025) | TGRS Research Map | TGRS